Gastrointestinal Stromal Tumors: Disease and Treatment Update

被引：27
作者：
Ho, Maria Y. [1 ]
Blanke, Charles D. [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver Clin, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
IMATINIB MESYLATE; C-KIT; KINASE INHIBITOR; TYROSINE KINASE; MUTATIONS; ACTIVATION; DIAGNOSIS; RECURRENCE; EXPRESSION; STI571;
D O I：
10.1053/j.gastro.2011.03.017
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1372 / U39
页数：7
相关论文
共 46 条
[1]   NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic and genotypic characteristics [J].
Andersson, J ;
Sihto, H ;
Meis-Kindblom, JM ;
Joensuu, H ;
Nupponen, N ;
Kindblom, LG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1170-1176
[2]   Gastrointestinal Stromal Tumor: Role of Interventional Radiology in Diagnosis and Treatment [J].
Avritscher, Rony ;
Gupta, Sanjay .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (01) :129-+
[3]   Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec [J].
Bechtold, RE ;
Chen, MYM ;
Stanton, CA ;
Savage, PD ;
Levine, EA .
ABDOMINAL IMAGING, 2003, 28 (06) :808-814
[4]   We should desist using RECIST, at least in GIST [J].
Benjamin, Robert S. ;
Choi, Haesun ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Charnsangavej, Chuslip .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764
[5]   Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].
Blanke, Charles D. ;
Demetri, George D. ;
von Mehren, Margaret ;
Heinrich, Michael C. ;
Eisenberg, Burton ;
Fletcher, Jonathan A. ;
Corless, Christopher L. ;
Fletcher, Christopher D. M. ;
Roberts, Peter J. ;
Heinz, Daniela ;
Wehre, Elisabeth ;
Nikolova, Zariana ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625
[6]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[7]   ACTIVATION OF THE HUMAN C-KIT PRODUCT BY LIGAND-INDUCED DIMERIZATION MEDIATES CIRCULAR ACTIN REORGANIZATION AND CHEMOTAXIS [J].
BLUMEJENSEN, P ;
CLAESSONWELSH, L ;
SIEGBAHN, A ;
ZSEBO, KM ;
WESTERMARK, B ;
HELDIN, CH .
EMBO JOURNAL, 1991, 10 (13) :4121-4128
[8]   Small and microscopically detected gastrointestinal stromal tumours: an overview [J].
Chetty, Runjan .
PATHOLOGY, 2008, 40 (01) :9-12
[9]   Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].
Choi, Haesun ;
Charnsangavej, Chuslip ;
Faria, Silvana C. ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Benjamin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759
[10]   Molecular pathobiology of gastrointestinal stromal sarcomas [J].
Corless, Christopher L. ;
Heinrich, Michael C. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2008, 3 :557-586
12345